Equity Profile

NUVL

Nuvalent, Inc.

Health CareBiotechnology$9.2B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Nuvalent, Inc. is a biotechnology company focused on developing targeted therapies for cancer....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs.

$-1.38

Revenue

Although no revenue is expected this quarter, any updates on future revenue streams could be crucial for investor confidence.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

NUVL Q2-2026 Earnings Preview

Context

Company Snapshot

Nuvalent, Inc. is a biotechnology company focused on developing targeted therapies for cancer. With a market cap of $9 billion, it operates in the health care sector, which is increasingly important as innovative treatments are in high demand.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

Avg EPS Surprise

-12.50%

Avg Stock Reaction

-1.06%

Last Quarter Recap

In Q1-2026, Nuvalent reported an EPS of $-1.39, slightly missing the estimate of $-1.35. The stock reacted negatively, dropping 1.78% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are expecting another loss this quarter, with a consensus EPS of $-1.38. Investors are looking for any signs of progress in Nuvalent's drug development pipeline.

Bull Case

If the company can demonstrate advancements in its therapies or provide positive updates on clinical trials, it could boost investor confidence and lead to a stock price increase.

Bear Case

Continued losses and lack of revenue could raise concerns about the company's long-term viability, leading to further declines in stock price.

Key Metrics to Watch

EPS

$-1.38

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs.

Revenue

$0M

Although no revenue is expected this quarter, any updates on future revenue streams could be crucial for investor confidence.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific updates can management provide on the progress of its drug development pipeline?

Investors will closely watch for any advancements or setbacks that could impact future revenue potential.

Will there be any guidance on expected timelines for future clinical trials?

Timelines for clinical trials can significantly affect investor sentiment and expectations for future earnings.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Nuvalent's therapies to gain traction in the market, especially if they provide positive trial results.

Supporting Evidence

Despite a lack of revenue, any positive news on drug trials could shift sentiment quickly.

The options market is pricing in a relatively small move, which may not reflect the potential volatility surrounding the earnings report.

Key Risk

If any positive updates on drug trials are announced, it could challenge the current consensus of continued losses.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on the company's ability to show progress in its drug pipeline amidst ongoing financial losses.

Bull Confirmed If

Positive updates on drug trials or potential partnerships could lead to a significant stock price increase.

Bear Confirmed If

Any indication of delays in drug development or continued losses could confirm bearish sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±3.9%

Historical Avg

±3.9%

In line with history

The options market is pricing in a modest move of about 3.9%, indicating uncertainty around the earnings report.

Options are pricing ±3.9% while NUVL has averaged ±3.9% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

0.4%

30d HV

31.9%

Calls (3K)P/C Ratio: 0.36Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Nuvalent beats expectations and raises guidance, history suggests the stock could rise by around 3.9% on the first day.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may experience a muted reaction.

Miss

Should the company miss expectations again, history suggests a potential decline of around 1.06% on the next trading day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of ongoing clinical trials and any new data.
2Management's commentary on future revenue potential and timelines.
3Any partnerships or collaborations that could enhance drug development.
4Insights into cost management strategies and how they plan to reduce losses.
5Discussion on market trends and how Nuvalent plans to position itself.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Nuvalent, Inc. is a biotechnology company focused on developing targeted therapies for cancer....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs.

$-1.38

Revenue

Although no revenue is expected this quarter, any updates on future revenue streams could be crucial for investor confidence.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

NUVL Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

Avg EPS Surprise

-12.50%

Avg Stock Reaction

-1.06%

Last Quarter Recap

In Q1-2026, Nuvalent reported an EPS of $-1.39, slightly missing the estimate of $-1.35. The stock reacted negatively, dropping 1.78% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are expecting another loss this quarter, with a consensus EPS of $-1.38. Investors are looking for any signs of progress in Nuvalent's drug development pipeline.

Bull Case

If the company can demonstrate advancements in its therapies or provide positive updates on clinical trials, it could boost investor confidence and lead to a stock price increase.

Bear Case

Continued losses and lack of revenue could raise concerns about the company's long-term viability, leading to further declines in stock price.

Key Metrics to Watch

EPS

$-1.38

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs.

Revenue

$0M

Although no revenue is expected this quarter, any updates on future revenue streams could be crucial for investor confidence.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific updates can management provide on the progress of its drug development pipeline?

Investors will closely watch for any advancements or setbacks that could impact future revenue potential.

Will there be any guidance on expected timelines for future clinical trials?

Timelines for clinical trials can significantly affect investor sentiment and expectations for future earnings.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Nuvalent's therapies to gain traction in the market, especially if they provide positive trial results.

Supporting Evidence

Despite a lack of revenue, any positive news on drug trials could shift sentiment quickly.

The options market is pricing in a relatively small move, which may not reflect the potential volatility surrounding the earnings report.

Key Risk

If any positive updates on drug trials are announced, it could challenge the current consensus of continued losses.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on the company's ability to show progress in its drug pipeline amidst ongoing financial losses.

Bull Confirmed If

Positive updates on drug trials or potential partnerships could lead to a significant stock price increase.

Bear Confirmed If

Any indication of delays in drug development or continued losses could confirm bearish sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±3.9%

Historical Avg

±3.9%

In line with history

The options market is pricing in a modest move of about 3.9%, indicating uncertainty around the earnings report.

Options are pricing ±3.9% while NUVL has averaged ±3.9% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

0.4%

30d HV

31.9%

Calls (3K)P/C Ratio: 0.36Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Nuvalent beats expectations and raises guidance, history suggests the stock could rise by around 3.9% on the first day.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may experience a muted reaction.

Miss

Should the company miss expectations again, history suggests a potential decline of around 1.06% on the next trading day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of ongoing clinical trials and any new data.
2Management's commentary on future revenue potential and timelines.
3Any partnerships or collaborations that could enhance drug development.
4Insights into cost management strategies and how they plan to reduce losses.
5Discussion on market trends and how Nuvalent plans to position itself.